Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
Study context
- Population
- ACS patients undergoing first isolated coronary artery bypass grafting (CABG) at Nordic cardiac surgery centresplanned enrollment
- Participants
- 2,200 patients
- Planned comparison
- DAPT vs acetylsalicylic acid (ASA) only after CABG
- Primary endpoint
- Composite of:
- Time to all-cause death
- MI
- Stroke
- New coronary revascularization
- Follow-up
- 12 months after randomization
Methodological detailsinvestigator-initiated, pragmatic, prospective, multinational, multicentre, open-label, registry-based, 1:1 randomisation, End points assessed via health care registries, Follow-up 10 years, Primary safety end point: time to hospitalization due to major bleeding, Secondary efficacy end points: individual components of the primary end point, CV death, rehospitalization for CV causes
- Investigator-initiated
- Pragmatic
- Prospective
- Multinational
- Multicentre
- Open-label
- Registry-based
- 1:1 randomisation
- End points assessed via health care registries
- Follow-up 10 years
- Primary safety end point: time to hospitalization due to major bleeding
- Secondary efficacy end points: individual components of the primary end point, CV death, rehospitalization for CV causes
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial. Am Heart J. Published 18 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it